+139%

est. 2Y upside i

Series D+

AI Powered Animal Diagnostics

Rank

#161

Sector

Veterinary Diagnostics

Est. Liquidity

~2Y

Data Quality

Data: Low

Moichor offers potential for high upside (140% expected) due to strong market position and AI moat, but execution risk is elevated given stale valuation, severe preference overhang, and high reliance on future funding.

Last updated: July 19, 2026

Bull (14%)+240%

Exit multiple expands to 12x due to IPO window or category leadership in AI diagnostics. Exit value $81M, common upside 300% capped, net of 20% dilution yields 240%.

Base (52%)+168%

Revenue grows to $6.75M, exit at 8x multiple ($54M). After preference and 20% dilution, common upside 168%.

Bear (34%)+51%

Multiple compresses to 5x ($33.75M exit). Common stock recovers $22.55M after preference, net of 20% dilution yields 50.7%.

Est. time to liquidity~2.0 years

Preference Stack Risk

severe

Funding Intensity

45%

$11.2M total funding vs $25M entry valuation – 45% preference overhang means common shareholders have a large senior claim ahead.

Dilution Risk

high

Last round was 41 months ago; company likely needs a down/flat round, diluting existing holders by ~20%.

Secondary Liquidity

none

No secondary market activity observed – lack of price discovery increases uncertainty.

Questions to Ask at the Interview

Strategic questions based on Moichor's data — designed to show you've done your homework.

  • 1

    “How does Moichor's AI and reference library create a defensible moat against incumbent diagnostics companies?”

  • 2

    “What is the recurring revenue mix from consumables versus device sales?”

  • 3

    “Given the 2023 funding round, what is the current runway and what milestones must be hit before the next raise?”

Community

Valuation Sentiment

Our model estimates +139% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.